HANGZHOU Solution in Bicuspid AS Undergoing TAVR

Inclusion Criteria: * Age ≥ 65 years * Age \<65 years and age ≥ 60 years with high surgical risk after combing STS Risk Estimate, Katz activities of Daily Living, major Organ System Dysfunction and Procedure-Specific Impediment; * Severe, bicuspid aortic stenosis: * Mean gradient ≥40 mmHg * Maximal aortic valve velocity ≥4.0 m/sec * Aortic valve area ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2) * NYHA classification ≥ II; * Type 0, type 1 (Sievers classification) by MDCT * Perimeter-derived annulus diameter ranges from 20.0 mm to 29.0 mm; * Transfemoral TAVR * The study patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB)/Ethics Committee (EC) of the respective clinical site. Exclusion Criteria: * Any contra-indication for Self-expanding bioprosthetic aortic valve deployment * Leukopenia (WBC \< 3000 cell/mL), acute anemia (Hgb \< 9 g/dL), Thrombocytopenia (Plt\< 50,000 cell/mL). * Active sepsis, including active bacterial endocarditis with or without treatment; * Evidence of an acute myocardial infarction ≤ 1 month (30 days) before the intended treatment \[(defined as: Q wave MI, or non-Q wave MI with total CK elevation of CK-MB ≥ twice normal in the presence of MB elevation and/or troponin level elevation (WHO definition)\]. * Stroke or transient ischemic attack (TIA) within 3 months (90 days) of the procedure. * Estimated life expectancy \< 12 …